Phase III trial of citrate/heparin/taurolidine (Neutrolin) for the prevention of catheter-related infections in cancer patients receiving total parenteral nutrition

Trial Profile

Phase III trial of citrate/heparin/taurolidine (Neutrolin) for the prevention of catheter-related infections in cancer patients receiving total parenteral nutrition

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Citrate/heparin/taurolidine (Primary)
  • Indications Bacterial infections; Catheter infections; Catheter thrombosis; Mycoses
  • Focus Registrational; Therapeutic Use
  • Acronyms LOCK-IT 200
  • Sponsors CorMedix
  • Most Recent Events

    • 15 Sep 2016 According to CorMedix media release, company may submit this and the other study (700250714) to the FDA for potential approval for both patient populations.
    • 05 Aug 2016 According to a CorMedix media release, company anticipates a meeting with the FDA to finalize the protocol in 4Q 2016.
    • 11 May 2016 According to a CorMedix media release, the company is planning to initiate pharmacoeconomic studies within LOCK-IT 100 and LOCK-IT 200 studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top